The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1758-2652
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1, 12.2010

Urheber
Stellbrink, HJ
Beteiligte Personen und Organisationen
Rugina, S.
Zagler, C.
Esser, S.
Castagna, A.
Gazzard, B.
Hill, A.
van Delft, Y.
Marks, S.
SpringerLink (Online service)

DOI
10.1186/1758-2652-13-S4-O47
URN
urn:nbn:de:1111-2016052060205
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:52 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Stellbrink, HJ
  • Rugina, S.
  • Zagler, C.
  • Esser, S.
  • Castagna, A.
  • Gazzard, B.
  • Hill, A.
  • van Delft, Y.
  • Marks, S.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal

Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study

The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patients

The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patients

Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Response of treatment-naive brain metastases to stereotactic radiosurgery

Response of treatment-naive brain metastases to stereotactic radiosurgery

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients

Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression

Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

Verbundene Objekte